OMGA.Omega Therapeutics, INC

Form 4: Omega Therapeutics Director, Richard A. Young, Acquires 25,000 Stock Options

Sentiment:

SEC Form 4 Filing

📋All filings for Omega Therapeutics, INC
🔒Login to Follow

Director Richard A. Young acquired 25,000 stock options in Omega Therapeutics, Inc. on June 20, 2024.

Summary

  • Richard A. Young, a director of Omega Therapeutics, Inc., acquired 25,000 stock options on June 20, 2024.
  • The exercise price of these options is $2.20.
  • The options vest on the earlier of the next annual meeting of stockholders or the first anniversary of the grant date (June 20, 2025), contingent upon continued service on the Board of Directors.
  • The options expire on June 19, 2034.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a standard disclosure of stock option grants to a director.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, such as directors, offering insights into their confidence in the company's future performance.

Stakeholder Impact

  • The acquisition of stock options by a director can signal confidence in the company's future, potentially positively influencing shareholder sentiment.

Key Dates

DateDescription
06/20/2024Date of transaction: Richard A. Young acquired 25,000 stock options.
06/20/2024Date of grant: Stock options granted to Richard A. Young.
06/20/2025Earliest vesting date: Options vest on the earlier of the next annual meeting of stockholders or this date.
06/19/2034Expiration date: Stock options expire.
06/21/2024Date of signature on the Form 4 filing.

Keywords

Stock Options, Form 4, Omega Therapeutics, Director, Acquisition, OMGA, Richard A. Young

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.